Positive signs for Monte Rosa in early data

21 March 2025

Monte Rosa Therapeutics (Nasdaq: GLUE), a US biotech developing novel molecular glue degrader (MGD)-based medicines, closed Thursday’s trading more than 5% higher.

The company earlier announced an update on MRT-6160, which is part of an agreement with Swiss pharma giant Novartis (NOVN: VX) announced last year worth $150 million upfront and up to $2.1 billion in total.

These results of the MRT-6160 Phase I SAD/MAD study demonstrate deep VAV1 degradation of greater than 90%, significant T and B cell functional inhibition, as well as significant inhibition of cytokine release from T and B cells following ex-vivo stimulation, and a favorable safety profile.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK